New drug combo aims to shrink breast tumors before surgery, spare chemo

NCT ID NCT05069038

Ongoing Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether giving the drug palbociclib (Ibrance) together with hormone therapy (letrozole, plus goserelin for premenopausal women) before surgery can shrink early-stage hormone receptor-positive, HER2-negative breast tumors. The study enrolls 51 patients with stage IIA to IIIC disease. The goal is to improve surgical outcomes and offer a gentler alternative to chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib (Ibrance) combined with letrozole and possibly goserelin
What this could lead to: If successful, this could offer a more effective, less toxic pre-surgery treatment option for early-stage hormone receptor-positive breast cancer, potentially reducing the need for chemotherapy.
What could go wrong: This is a small, early-phase (phase II) trial with only 51 participants, so results may not apply to all patients. Side effects like low white blood cell counts (neutropenia) are a known risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Unversity of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.